

4 NOVEMBER, 2022



This is Lundbeck

Prof Morten Grunnet, PhD, Vice President Neuroscience

Being Premier in Neuroscience



Focus on
promising biology



De-risking early
in development
(biomarkers)



Integrate patient insights
in everything we do

Let the
biology
speak

Let the
molecule
speak

Let the
patient
speak


Let the organization speak

Premier in Neuroscience

Focus on promising biology


Four biology clusters feeding into our strategy

- Scientifically well-described areas still rich in targets with untapped potential
- High feasibility for early de-risking and maintaining a competitive edge



**Modality agnostic approach to drug discovery,
driven by target-specific requirements**

The “translational gap”



Questions to be addressed

- We have two different approaches to sleep disorders – Sleep disorders *per se* (narcolepsy, insomnia, ect) and sleep disturbances related to brain disorders
- We use sleep assessment across clinical studies (search for indication, basket trials) so qualify directionality and indication choices in our clinical programs
- Can we move from pseudospecificity to real indications?
 - Is it possible to create understanding of specific neuronal pathways that drives sleep disturbances in a given disease or indication (PD, AD, PAIN)?
- What will it take to generate enough evidence to have specific indications in the sleep area?
- Causality vs consequence – We need to strengthen the causality part of that equation to enable investment in new drugs